sarmad nory gany aldujaili

soriatic patients with plaque psoriasis particularly those with high body mass index have increasing risk of developing a diabetes mellitus type 2 (DM2) and hyperlipidemia. Since both conditions are associated with dysregulation in DPP-IV, DPP-IV inhibitors have been suggested as therapeutic drugs for both diseases. Sitagliptin yields a significant decrease in serum concentration of TG, LDL and cholesterol in diabetic patients particularly those with high baseline TG levels and those using statins. To determine the effect of sitagliptin on lipid profiles and their correlation with PASI score in psoriatic patients with DM. The study was conducted on 50 diabetic patients with moderate to severe plaque psoriasis who were divided into two groups: Placebo group (n=25) Patients were administered placebo 100mg once daily plus dietary control and exercise for 3 months; Sitagliptin group (n=25) Patients were administered sitagliptin tablet 100mg once a day plus dietary control and exercise for 3 months. PASI score for all patients was assessed before and after 12 weeks of treatment. The blood samples were obtained from the patients in both groups at baseline and after 12 week of therapy were used to measure the concentration of triglyceride (TG), cholesterol, low density lipoprotein(LDL), very low density lipoprotein(VLDL) and high density lipoprotein(HDL). Compared with baseline in sitagliptin group and control group after 12week, the level of TG, cholesterol, LDL, and VLDL were significantly reduced and correlated with PASI score after 12 week of sitagliptin treatment (P < 0.05), in contrast the level of HDL was significantly increased with a negative correlation with PASI score (P < 0.05). The current results revealed that sitagliptin improves psoriasis possibly via a reduction in lipid profiles which were significantly correlated with PASI score. © 2016, SILAE (Italo-Latin American Society of Ethnomedicine). All rights reserved.

Psoriatic patients with plaque psoriasis particularly those with high body mass index have increasing risk of developing a diabetes mellitus type 2 (DM2) and hyperlipidemia. Since both conditions are associated with dysregulation in DPP-IV, DPP-IV inhibitors have been suggested as therapeutic drugs for both diseases. Sitagliptin yields a significant decrease in serum concentration of TG, LDL and cholesterol in diabetic patients particularly those with high baseline TG levels and those using statins. To determine the effect of sitagliptin on lipid profiles and their correlation with PASI score in psoriatic patients with DM. The study was conducted on 50 diabetic patients with moderate to severe plaque psoriasis who were divided into two groups: Placebo group (n=25) Patients were administered placebo 100mg once daily plus dietary control and exercise for 3 months ; Sitagliptin group (n=25) Patients were administered sitagliptin tablet 100mg once a day plus dietary control and exercise for 3 months. PASI score for all patients was assessed before and after 12 weeks of treatment. The blood samples were obtained from the patients in both groups at baseline and after 12 week of therapy were used to measure the concentration of triglyceride (TG), cholesterol, low density lipoprotein(LDL), very low density lipoprotein(VLDL) and high density lipoprotein(HDL). Compared with baseline in sitagliptin group and control group after 12week, the level of TG, cholesterol, LDL, and VLDL were significantly reduced and correlated with PASI score after 12 week of sitagliptin treatment (P < 0.05) , in contrast the level of HDL was significantly increased with a negative correlation with PASI score (P < 0.05). The current results revealed that sitagliptin improves psoriasis possibly via a reduction in lipid profiles which were significantly correlated with PASI scor

I attend Kurdistan derma which Held in March 2021 with Dr.Prof.Muhsen.Aldalmi and assistant Prof.Haider Al.sabaak